Cortechs.ai | Unlocking the Value of NeuroQuant Reports: Different Use Cases Across Clinical Practice

Unlocking the Value of NeuroQuant Reports: Different Use Cases Across Clinical Practice

Quantitative neuroimaging has become a cornerstone of precision medicine. NeuroQuant automatically transforms routine MRI scans into objective volumetric measurements, empowering clinicians to visualize, quantify, and track structural brain changes with reproducibility and confidence.

NeuroQuant provides standardized data that enhance clinical interpretation across a range of neurological conditions, including neurodegeneration, trauma, epilepsy, and developmental disorders. NeuroQuant’s 5 standard, disease-specific reports help drive precision in disease management by providing data on relevant structural volumes. 

Dementia and Age-Related Atrophy Report: Tracking Neurodegeneration and Hippocampal Occupancy 

The NeuroQuant Dementia Report quantifies key brain structures involved in neurodegenerative disease, comparing volumes to an age‑ and sex‑matched normative database. Percentile rankings help identify deviations from expected ranges to provide insight into patient clinical condition. 

The structures included in the Dementia Report include hippocampi, entorhinal cortex, superior and inferior lateral ventricles, whole brain, lobar cortices, anterior cingulate cortex, and posterior cingulate cortex. This report also includes hippocampal occupancy (HOC) score, an indicator of the balance between hippocampal and inferior lateral ventricle volumes, to help assess mesial temporal lobe atrophy often observed as a hallmark pattern of Alzheimer’s disease.  

Key use cases: 

  • Early detection of hippocampal and temporal lobe atrophy in mild cognitive impairment (MCI) 
  • Support of differentiation between Alzheimer’s‑type, frontotemporal, and other atrophic patterns 
  • Longitudinal tracking of disease progression or treatment response 
  • Objective measurement for patient follow‑up and clinical trials 

Cortechs.ai | Unlocking the Value of NeuroQuant Reports: Different Use Cases Across Clinical Practice

Multi‑Structure Atrophy Analysis: Beyond the Hippocampus 

While hippocampal atrophy is a hallmark of Alzheimer’s disease, multi‑structure atrophy can provide additional insight into other neurodegenerative syndromes. NeuroQuant Multi-Structure Atrophy (MSA) Report evaluates volumetric data across cortical and subcortical structures, allowing clinicians to visualize disease‑specific signatures. 

The structures included on the MSA report include whole brain, cortical gray matter, cerebral white matter, hippocampi, thalami, superior and inferior later ventricles, and 3rd ventricle.  

Key use cases: 

  • Atypical Parkinsonism 
  • Normal pressure hydrocephalus 
  • Multiple Sclerosis-related volume loss 
  • Subcortical atrophy 

Cortechs.ai | Unlocking the Value of NeuroQuant Reports: Different Use Cases Across Clinical Practice

Total Brain Atrophy: Objective Evaluation After Injury 

In traumatic brain injury (TBI), subtle diffuse atrophy can be difficult to visualize qualitatively. Total Brain Atrophy Report compares regional volumes to normative data to highlight structural changes resulting from injury. This comprehensive report contains data on 37 key structures.

Key use cases: 

  • Quantifying atrophy in frontal, temporal, or subcortical regions 
  • Assessing global patterns of abnormal percentile calculations 
  • Identifying right to left asymmetry 

Cortechs.ai | Unlocking the Value of NeuroQuant Reports: Different Use Cases Across Clinical Practice

Pediatric Brain Development Report: Assessing Growth and Maturation 

NeuroQuant’s Pediatric Report compares individual brain structure volumes to an age‑ and sex‑matched normative database from childhood through adolescence. 

The structures included in the Pediatric Brain Development Report include whole brain, cerebral white matter, cortical gray matter, lobar cortices, cerebellum, and ventricles. 

Key use cases: 

  • Evaluating developmental delays or macro/microcephaly 
  • Tracking structural maturation in conditions like autism spectrum disorder (ASD) or ADHD 
  • Quantifying volumetric differences in pediatric epilepsy or metabolic disorders 
  • Longitudinal follow‑up during neurodevelopmental intervention programs

Cortechs.ai | Unlocking the Value of NeuroQuant Reports: Different Use Cases Across Clinical Practice

Seizure and Hippocampal Asymmetry: Quantitative Epilepsy Assessment 

In epilepsy and seizure disorders, hippocampal asymmetry is a critical biomarker that can influence surgical planning and diagnosis. 

The NeuroQuant Seizure report quantifies right and left hippocampal volumes and assigns an asymmetry index to evaluate unilateral conditions.  

Key use cases: 

  • Measuring unilateral hippocampal volume loss in temporal lobe epilepsy (TLE) 
  • Establishing objective pre‑ and post‑surgical volumetric baselines 
  • Documenting hippocampal sclerosis progression in chronic epilepsy

Cortechs.ai | Unlocking the Value of NeuroQuant Reports: Different Use Cases Across Clinical Practice

Conclusion 

NeuroQuant brings quantitative consistency to brain MRI, enabling clinicians to move beyond subjective impressions toward objective, data‑driven insights. From neurodegeneration and demyelination to pediatric development, trauma, and seizure disorders, its suite of reports supports better decision‑making, clearer communication, and longitudinal patient care.

More Resources

03/13/2026

Cortechs Cares: Community Impact and Volunteer Efforts in 2025

Cortechs Cares highlights how our team gave back in 2025 through community volunteer efforts, including an Alzheimer’s Walk and holiday toy drive.

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.
Scroll to Top